LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer that cannot be removed by surgery (unresectable) and/or has spread to other places in the body (metastatic). Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. LY3214996 and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving LY3214996 and cetuximab alone or in combination with abemaciclib may help treat patients with colorectal cancer.

本Ib/II期临床试验旨在探究LY3214996联合西妥昔单抗（cetuximab）单药，或联合西妥昔单抗与阿贝西利（abemaciclib）时的不良反应与最佳给药剂量，并评估上述方案治疗无法通过手术切除（不可切除）且/或已发生远处转移的结直肠癌患者的临床疗效。西妥昔单抗属于单克隆抗体，可干扰肿瘤细胞的生长与扩散能力；LY3214996与阿贝西利则可通过阻断细胞生长所需的部分酶，抑制肿瘤细胞增殖。将LY3214996与西妥昔单抗单药联合，或与西妥昔单抗及阿贝西利联合使用，或可用于结直肠癌患者的治疗。